1.Osborne, K, et al. Ten years of serological surveillance in England and Wales: methods, results, implications and action. International Journal of Epidemiology 2000; 29: 362–368.
2.Osborne, K, Weinburg, J, Miller, E. The European Seroepidemiology Network. Eurosurveillance 1997; 2: 29–31.
3.Gabutti, G, et al. The epidemiology of mumps in Italy. Vaccine 2008; 26: 2906–2911.
4.de Melker, HE, Conyn-van Spaendonck, MA. Immunosurveillance and the evaluation of national immunization programmes: a population-based approach. Epidemiology and Infection 1998; 121: 637–643.
5.Vandermeulen, C, et al. Vaccination coverage in 14-year-old adolescents: Documentation, timeliness, and sociodemographic determinants. Pediatrics 2008; 121: E428–E434.
6.Swennen, B, et al. Analysis of factors influencing vaccine uptake: perspectives from Belgium. Vaccine 2001; 20: S5–S7.
7.Theeten, H, et al. Coverage of recommended vaccines in children at 7–8 years of age in Flanders, Belgium. Acta Paediatrica 2009; 98: 1307–1312.
8.Swennen, B, Robert, E. Vaccination coverage survey in infants at 18–24 months of age in the French region (excluding Brussels). Brussels, Belgium: PROVAC-Université Libre de Bruxelles; November 2009.
9.Theeten, H, et al. Infant vaccination coverage in 2005 and predictive factors for complete or valid vaccination in Flanders, Belgium: an EPI-survey. Vaccine 2007; 25: 4940–4948.
10.Mathei, C, et al. Diphtheria immunity in Flanders. European Journal of Clinical Microbiology & Infectious Diseases 1997; 16: 631–636.
11.Andrews, N, et al. Towards elimination: measles susceptibility in Australia and 17 European countries. Bulletin of the World Health Organization 2008; 86: 197–204.
12.Nardone, A, et al. Comparison of rubella seroepidemiology in 17 countries: progress towards international disease control targets. Bulletin of the World Health Organization 2008; 86: 118–125.
13.Edmunds, WJ, et al. The sero-epidemiology of diphtheria in Western Europe. ESEN Project. European Sero-Epidemiology Network. Epidemiology and Infection 2000; 125: 113–125.
14.Anon. Diphtheria vaccine. WHO Weekly Epidemiological Record 2006; 3: 24–32.
15.Anon. Tetanus vaccine. WHO Weekly Epidemiological Record 2006; 20: 198–208.
16.Gergen, PJ, et al. A population-based serologic survey of immunity to tetanus in the United States. New England Journal of Medicine 1995; 332: 761–766.
17.Skendzel, LP. Rubella immunity. Defining the level of protective antibody. American Journal of Clinical Pathology 1996; 106: 170–174.
18.Anon. Total and Belgian population at 1 January 2006. Brussels: FPS Economy, General Directorate Statistics and Economic Information, 2009. Report No. S220.A1N/2006.
19.WHO. Eliminating measles and rubella and preventing congenital rubella infection: WHO European Region strategic plan 2005–2010. Copenhagen, Denmark: WHO Regional Office for Europe; 2006. Report No.: ISBN 92 890 1382 6.
20.Boonen, M, et al. Vaccination coverage in infants and adolescents in Flanders. Vlaams Infectieziektenbulletin 2009; 68: 9–14.
21.Vander Veken, J, Van Casteren, V. Surveillance of measles and mumps by sentinel family physicians in Belgium, 1982–1993. Brussels: Institute of Public Health, 1994. Report No.: D/1994/2505/29.
22.Beutels, P, et al. The difficult quest for data on ‘vanishing’ vaccine-preventable infections in Europe: the case of measles in Flanders (Belgium). Vaccine 2002; 20: 3551–3559.
23.Amela, C, Pachon, I, de Ory, F. Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey. European Journal of Epidemiology 2002; 18: 71–79.
24.Mossong, J, Putz, L, Schneider, F. Seroprevalence of measles, mumps and rubella antibodies in Luxembourg: results from a national cross-sectional study. Epidemiology and Infection 2004; 132: 11–18.
25.Tischer, A, Gerike, E. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella. Vaccine 2000; 18: 1382–1392.
26.Lernout, T, et al. An outbreak of measles in orthodox Jewish communities in Antwerp, Belgium, 2007–2008: different reasons for accumulation of susceptibles. Eurosurveillance 2009; 14: 15–18.
27.Chen, RT, et al. Measles antibody – reevaluation of protective titers. Journal of Infectious Diseases 1990; 162: 1036–1042.
28.Ratnam, S, et al. Comparison of commercial enzyme-immunoassay kits with plaque reduction neutralization test for detection of measles-virus antibody. Journal of Clinical Microbiology 1995; 33: 811–815.
29.Samb, B, et al. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatric Infectious Disease Journal 1995; 14: 203–209.
30.Vandermeulen, C, et al. Outbreak of mumps in a vaccinated child population: a question of vaccine failure? Vaccine 2004; 22: 2713–2716.
31.Briss, PA, et al. Sustained transmission of mumps in a highly vaccinated population – assessment of primary vaccine failure and waning vaccine-induced immunity. Journal of Infectious Diseases 1994; 169: 77–82.
32.Sabbe, M, Hue, D. Surveillance of infectious diseases in children in Belgium. Pedisurv, annual report 2008. 2009. Report No.: IPH/EPIREPORTS no. 2008-052.
33.Plotkin, SA, Reef, S. Rubella vaccine. In: Plotkin, SA, Orenstein, WA, Offit, P, eds. Vaccines, 5th edn. Philadelphia: Saunders, Elsevier, 2008, pp. 735–771.
34.Vyse, AJ, et al. Interpreting serological surveys using mixture models: the seroepidemiology of measles, mumps and rubella in England and Wales at the beginning of the 21st century. Epidemiology and Infection 2006; 134: 1303–1312.
35.Vandermeulen, C. 25 years of measles-mumps-rubella vaccination. Epidemiological and immunological considerations regarding mumps (dissertation). Leuven, Belgium: Katholieke Universiteit Leuven, 2009, pp. 1–164.
36.Kafatos, G, Andrews, N, Nardone, A. Model selection methodology for inter-laboratory standardisation of antibody titres. Vaccine 2005; 23: 5022–5027.
37.Tischer, A, et al. Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia. Epidemiology and Infection 2007; 135: 787–797.
38.Thomas, C, Moridani, M. Interindividual variations in the efficacy and toxicity of vaccines. Toxicology (in press).
39.Anderson, R, May, R. Immunisation and herd immunity. Lancet 1999; 335: 641–645.
40.Stubbe, M, et al. Seroprotection against tetanus in patients attending an emergency department in Belgium and evaluation of a bedside immunotest. European Journal of Emergency Medicine 2007; 14: 14–24.
41.Olander, RM, et al. High tetanus and diphtheria antitoxin concentrations in Finnish adults – time for new booster recommendations? Vaccine 2009; 27: 5295–5298.
42.Kelly, H, et al. A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia. Vaccine 2002; 20: 3130–3136.
43.Rota, MC, et al. Measles serological survey in the Italian population: interpretation of results using mixture model. Vaccine 2008; 26: 4403–4409.